Biphasic Regulation of Breast Cancer Cell Growth by Progesterone: Role of the Cyclin-Dependent Kinase Inhibitors, p21 and p27Kip1
Steve D. Groshong,
Gareth I. Owen,
Bryn Grimison,
Irene E. Schauer,
Maria C. Todd,
Thomas A. Langan,
Robert A. Sclafani,
Carol A. Lange and
Kathryn B. Horwitz
University of Colorado Health Sciences Center, Departments of
Medicine and Pathology (G.I.O., C.A.L., K.B.H.), Department of
Biochemistry, Biophysics and Genetics (I.E.S., R.A.S.), Department
of Pharmacology (M.C.T., T.A.L.), The Molecular Biology Program
(S.D.G., B.G., T.A.L., R.A.S., K.B.H.), Denver, Colorado 80262
 |
ABSTRACT
|
---|
Depending on the tissue, progesterone is
classified as a proliferative or a differentiative hormone. To explain
this paradox, and to simplify analysis of its effects, we used a breast
cancer cell line (T47D-YB) that constitutively expresses the B isoform
of progesterone receptors. These cells are resistant to the
proliferative effects of epidermal growth factor (EGF). Progesterone
treatment accelerates T47D-YB cells through the first mitotic cell
cycle, but arrests them in late G1 of the second cycle. This arrest is
accompanied by decreased levels of cyclins D1, D3, and E, disappearance
of cyclins A and B, and sequential induction of the cyclin-dependent
kinase (cdk) inhibitors p21 and p27Kip1. The
retinoblastoma protein is hypophosphorylated and extensively
down-regulated. The activity of the cell cycle-dependent protein
kinase, cdk2, is regulated biphasically by progesterone: it increases
initially, then decreases. This is consistent with the biphasic
proliferative increase followed by arrest produced by one pulse of
progesterone. A second treatment with progesterone cannot restart
proliferation despite adequate levels of transcriptionally competent
PR. Instead, a second progesterone dose delays the fall of p21 and
enhances the rise of p27Kip1, thereby
intensifying the progesterone resistance in an autoinhibitory loop.
However, during the progesterone-induced arrest, the cell cycling
machinery is poised to restart. The first dose of progesterone
increases the levels of EGF receptors and transiently sensitizes the
cells to the proliferative effects of EGF. We conclude that
progesterone is neither inherently proliferative nor antiproliferative,
but that it is capable of stimulating or inhibiting cell growth
depending on whether treatment is transient or continuous. We also
suggest that the G1 arrest after progesterone treatment is accompanied
by cellular changes that permit other, possibly tissue-specific,
factors to influence the final proliferative or differentiative state.
 |
INTRODUCTION
|
---|
Progesterone is involved in the development, growth, and
differentiation of the breast and breast cancers (1, 2), and presence
of progesterone receptors (PR) identifies tumors likely to be
hormone-dependent (3) and patients likely to have a favorable disease
prognosis (4). Mice lacking PR exhibit incomplete mammary gland ductal
branching and failure of lobulo-alveolar development (5). This
phenotype is strikingly similar to that of mice lacking cyclin D1 (6).
These and other studies (7, 8, 9) suggest important functional links among
progesterone, cyclin D1, and breast cancer and implicate the mitotic
cell cycle in progesterone-dependent differentiation of the breast.
Opposing views that progesterone is a proliferative hormone in the
breast are currently reflected in clinical practice (10, 11, 12).
Progestins are added to estrogens for hormone replacement therapy at
menopause because they block the proliferative and tumorigenic effects
of unopposed estrogens in the uterus. However, women who have been
hysterectomized are not given progestins, to spare their breasts from
the presumed proliferative effects of these hormones (13, 14, 15). This is
defended by the prevailing notion that progesterone is differentiative
in the uterus but proliferative in the breast (1, 2).
It is now clear that control of proliferation and differentiation by
many hormones and growth factors is linked by events that occur in G1
of the cell cycle (16, 17, 18, 19). Recent studies implicate up-regulation of
the cyclin-dependent kinase (cdk) inhibitors, particularly p21
(p21Kin1,Waf1,Sdi1) (20), not only in inhibiting cell
proliferation, but in promoting differentiation. In contrast,
overexpression of cyclin D1 inhibits the differentiative program (21)
and, in the breast, promotes cellular hyperplasia and tumor formation
(9).
The molecular mechanisms underlying the proliferative and
differentiative effects of progesterone at its target tissues have been
difficult to assess for several reasons (2, 6). First, in most
progesterone target cells the levels of PR are regulated by estradiol
(22). Therefore, obligatory pretreatment with estradiol, itself a
potent proliferative agent (23), confounds assessment of
progesterones role on growth and other cellular processes. Second, as
Musgrove et al. (24) have shown, short-term progestin
treatments have dual effects on the cell cycle: they inhibit reentry of
cells from mitosis into G1, but stimulate progression of cells through
G1 (24). This complicates analysis of the role of progesterone in
regulating proliferation acutely. The mechanisms underlying its
sustained effects are unknown. Third, progesterone target tissues
contain two isoforms of PR, the 120-kDa B receptors and the
N-terminally truncated 94-kDa A receptors (25), that have unequal
transcriptional activities (26, 27, 28). Additionally, the two isoforms are
dissimilarly regulated and expressed during development, after hormone
treatments, and in different target tissues and tumors (29, 30, 31, 32).
Our approach to reconciling these complexities, which limit studies of
progesterone actions, has been to construct simpler model systems. To
that end, we have used the T47DCO human breast cancer cell
line, in which the two PR isoforms have escaped from estrogen controls
and are constitutively expressed (33), to isolate the effects of
progesterone and eliminate the confounding effects of estradiol. To
define the role of each receptor isoform, we recently isolated and
subcloned a PR-negative subline of T47DCO called T47D-Y and
used it as the recipient into which either the B- or A isoform of PR
was stably reintroduced to produce T47D-YB and T47D-YA cells (34).
In the present study, we used T47D-YB cells to analyze the effects of
acute and sustained progesterone on the factors that regulate cell
cycle progression and integrate growth-regulatory signals. This
includes measurement of the protein levels of key cyclins (35, 36, 37, 38, 39); the
levels and phosphorylation state of the retinoblastoma (Rb) tumor
suppressor (40); the levels of cdk inhibitors (36, 41); and the kinase
activity of cdk2 (17, 35, 37, 38, 39). Since T47D-YB cells are resistant to
the proliferative effects of epidermal growth factor (EGF), we analyzed
the role of cross-talk between the progesterone- and EGF-signaling
pathways, on these proliferative events.
We find that after stimulating one round of cell division, a
single pulse of progesterone arrests T47D-YB cells in late G1 of the
second cycle, by sequentially raising the levels, first of p21 and then
of p27Kip1. This is accompanied by an induction followed by
inhibition of cdk2 activity. A second progesterone dose augments the
growth arrest. However, during the arrested state, the cells become
responsive to the proliferative effects of EGF, which can cause them to
resume cycling. This occurs only after a single progesterone pulse; a
second progesterone dose delays the p21 fall and blocks EGF
responsiveness. We propose that progesterone is neither inherently
proliferative nor antiproliferative, but that its effects on growth
depend on whether treatment is transient or continuous; the former is
stimulatory and the latter inhibitory. Additionally, cell cycle arrest
in G1 may be accompanied by progesterone-induced cellular changes that
can be permissive for growth-stimulatory effects by other factors.
 |
RESULTS
|
---|
Progesterone Treatment Leads to Growth Resistance Despite
Functional PR
To study the proliferative effects of progestins, parallel sets of
PR-negative Y cells (Fig. 1
, panel A), A
receptor-containing YA cells (panels B and D), and B
receptor-containing YB cells (panels C and E), were grown in control
medium or in medium containing the following additions: the synthetic
progestin agonist R5020 alone; the antiprogestins RU486 or ZK98299; or
R5020 plus one of the antiprogestins. Sets of cells were harvested
every 4 h for 48 h, and the percent in S+G2/M for
each treatment group was determined by flow cytometry. Optimal
concentrations for each hormone were determined in preliminary studies.
As shown in Fig. 1
, panel A, the percent of PR-negative Y cells in
S+G2/M during 50 h of treatment with 30 nM
R5020, 100 nM RU486, or 1 µM ZK98299 is no
different than untreated controls, supporting the idea that
proliferative responses to progestins and antiprogestins are dependent
on the presence of PR and ruling out any effects through glucocorticoid
receptors. These cells are also unresponsive to estradiol (not shown)
and EGF (see below). Compared with controls (set at 0), in either A
receptor (panels B and D) or B receptor (panels C and E) containing
cell lines, the percent of cells in S+G2/M starts to climb
approximately 12 h after R5020 is added to the medium, peaks at
2024 h, and returns to basal levels approximately 36 h later, as
previously reported (24). During this transient increase in mitotic
activity, the percent of cells in S+G2/M rises from basal
levels of approximately 1520% in the untreated controls, to 4550%
in the R5020-treated sets. The two antiprogestins, RU486 or ZK98299,
when each is given alone, consistently have a transient
growth-suppressive effect that is more pronounced in the YA than in the
YB cells. However, in both cell lines, neither antagonist, when present
alone, has long-term growth-suppressive effects (data not shown). In
either cell line, the two antiprogestins completely block the
R5020-induced proliferative burst, suggesting again that growth effects
of progestins are PR-dependent. Since the two PR-containing cell lines
did not differ significantly, the remaining studies described here used
T47D-YB cells. Control of proliferation by antiprogestins in the
presence of cAMP does exhibit PR isoform specificity (K. Horwitz, in
preparation).

View larger version (30K):
[in this window]
[in a new window]
|
Figure 1. The Synthetic Progestin R5020 Induces a
Proliferative Burst in PR-Positive Cells That Is Inhibited by
Antiprogestins
A, PR-negative T47D-Y cells were treated with the agonist R5020 ( )
or the antiprogestins RU486 () or ZK98299 ( ) for 48 h. Cells
were harvested every 6 h, and the percent of cells in
S+G2/M was measured by flow cytometry. B, T47D-Y cells
stably expressing A receptors (YA) were treated with R5020 ( ), RU486
(), or both ( ), and cells in S+G2/M were measured by
flow cytometry over a 48-h period. C, T47D cells stably expressing B
receptors (YB) were treated with R5020 ( ), RU486 (), or both
( ). D, Same as panel B except that ZK98299 was the antiprogestin. E,
Same as panel C except that ZK98299 was the antiprogestin. Change in
percent of cells in S+G2/M is compared with controls, set
at zero. In this study approximately 1520% of control cells were in
S+G2/M.
|
|
Although R5020 is known to be poorly metabolized in T47DCO
cells (42), it was theoretically possible that the transitory nature of
the proliferative increase seen in Fig. 1
was due to degradation of the
hormone during the 40 or more hours of cell culture. To determine
whether additional hormone would produce a sustained rise in
proliferation, T47D-YB cells were treated with R5020 at time 0, then
given a second pulse of R5020 at 48 h, and the percent of cells in
different phases of the cell cycle was measured for 96 h (Fig. 2A
). Surprisingly, while the initial
proliferative rise at 20 h was clearly evident, the cells were
completely refractory to the second hormone challenge.

View larger version (37K):
[in this window]
[in a new window]
|
Figure 2. After the Initial Proliferative Burst, T47D-YB
Cells Are Resistant to Another Progestin Challenge Despite Adequate PR
Levels
A, T47D-YB cells were untreated or were treated with progesterone ( )
or R5020 () at 0 time, and again with R5020, 48 h later. Cells
were harvested every 46 h for 96 h. Percent cells in
S+G2/M were measured by flow cytometry. Changes in the
percent S+G2/M of hormone-treated cells are compared with
untreated controls, which were set at 0. B, T47D-YB cells were treated
with R5020 or progesterone at 0 time and harvested periodically for
50 h. B receptor levels were measured by immunoblotting with
anti-PR antibodies; hormone-untreated controls are shown at time 0.
|
|
We postulated that the resistance to additional R5020 at 40 h was
due to receptor down-regulation produced by the continuous exposure to
hormone. Indeed, while untreated control cells have high levels of PR B
receptors as measured by immunoblotting (Fig. 2B
), 10 h after the
start of R5020 treatment, B receptors are barely detectable. If the
cell culture medium is not changed, there is little recovery of
receptors for at least 50 h. However, as shown in Fig. 2B
, after
progesterone treatment, B receptor down-regulation is transitory:
receptor levels are depressed 10 h after the hormone addition, but
they rapidly replenish to control levels because this natural ligand is
metabolized in T47DCO cells with a half-life of 24 h
(42). We therefore postulated that T47D-YB cells are refractory to a
second hormone challenge after initial treatment with R5020 (Fig. 2A
)
because PR are still down-regulated at 40 h, and we reasoned that
if the cells were initially treated with progesterone, their progestin
sensitivity would be restored at 40 h. Figure 2A
shows that this
is not the case. Like R5020, progesterone produces a transient increase
in cell proliferation. Nevertheless, 40 h after the initial
progesterone-induced growth, and despite adequate levels of receptors
(Fig. 2B
), the cells are completely refractory to subsequent treatment
with R5020.
This result was surprising, and we wondered whether the replenished
receptors were somehow functionally incompetent (Fig. 3
). To test this, we measured the ability
of replenished receptors to activate transcription of chloramphenicol
acetyl transferase (CAT) driven by a PR-responsive promoter. Parallel
sets of YB cells were pretreated with progesterone at zero time.
Twenty-four hours later a subset of cells was transfected with the
PRE2-TATAtk-CAT reporter, in which the proximal
promoter of the thymidine kinase gene is controlled by two upstream
progesterone response elements (PRE). The cells were glycerol shocked
at 46 h to complete the transfection and immediately treated with
a second dose of either progesterone or R5020 for an additional 24
(Fig. 3
, inset) or 48 h (not shown) before they were
harvested, and CAT activity was measured in cell lysates. A control set
of transfected cells was left untreated at 40 h (Fig. 3
, inset). Additionally, parallel sets of untransfected
cultures were treated with a second pulse of R5020 at 40 h, and
the cells were harvested periodically over the next 48 h for
analysis of cell cycle phases by flow cytometry (Fig. 3
). As shown
above, after the initial progesterone-induced proliferative burst, the
cells enter a period of growth arrest, lasting at least 80 h, from
which they cannot be rescued by retreatment with R5020 at 40 h.
However as the inset (Fig. 3
) shows, this inhibition is not
due to incompetent receptors, since they can induce CAT transcription
in the same endocrine setting. Thus, despite progesterone pretreatment
at time zero, at 40 h R5020 and progesterone strongly induce
transcription from the PRE-TATAtk-CAT reporter. The control
cells that received no second hormone dose confirm that 40 h after
the initial progesterone dose, insufficient hormone remains in either
the cells or the medium from the primary treatment to transactivate the
promoter, so that the high levels of CAT activity seen in the 40-h
R5020- and progesterone treated sets must be due to the second dose. We
conclude that the replenished receptors are fully functional: they are
capable of binding ligand, of binding DNA at cognate PREs, and of
interacting with the requisite factors on a promoter to activate
transcription (43).

View larger version (48K):
[in this window]
[in a new window]
|
Figure 3. T47D-YB Cells Resistant to the Proliferative
Effects of Progestins Contain Transcriptionally Competent and
Hormone-Responsive PR
T47D-YB cells were treated with progesterone at time 0 and retreated
with progesterone at 40 h ( ), or left untreated ( ). Cells
were harvested every 46 h for 80 h, and the percent of cells in
S+G2/M was measured by flow cytometry.
Inset, YB cells treated with progesterone at time 0 were
transfected with the PRE2-TATAtk-CAT reporter
at 46 h and left untreated (-) or treated with R5020 or
progesterone. Cells were harvested 24 h later, lysates were
prepared, normalized to ß-galactosidase activity, and CAT activity
was measured by TLC. Duplicates from separate transfections are
shown.
|
|
Progesterone Produces G1 Phase Arrest by Up-Regulating p21 and
p27Kip1 and Inhibiting cdk2 Activity
Since recent studies suggest links among progesterone, breast
cancer, and the cell cycle (Refs. 59 and others), we measured the
protein levels of cell cycle-regulatory proteins during the dual
progestin treatment regimen, in an attempt to explain the progesterone
resistance. Figure 4
shows the changes in
protein levels over a 70-h period, of cyclins D1, D3, and E, of the
inhibitors p21 and p27Kip1, and of Rb. These proteins
regulate progression of cells through G1 (36, 39). The cells were
treated with progesterone at time zero, followed 40 h later by no
treatment or by R5020. The cells were harvested periodically, and
aliquots of cell lysates were assayed for the cell cycle proteins by
immunoblotting, and for the percent of cells in S+G2/M by
flow cytometry. In Fig. 4
, the flow cytometric data are shown by the
dashed line, since they represent the same data points that
are shown in detail in Fig. 3
. After primary treatment with
progesterone, the levels of cyclin D1 rise transiently and then fall as
previously reported (24), coincident with the increased proliferative
activity observed in the first 24 h. D1 expression increases
within 2 h of progesterone addition (not shown). A second abortive
peak is observed between 2540 h, and levels then fall again after
40 h. This second peak is not always observed; it is markedly
attenuated if the basal cell proliferation rate is relatively low. Note
that the study shown in Fig. 4
involves cells that have a rapid basal
proliferation rate, characteristically seen in late passages. The
changes in D3 levels resemble those of D1, in which an initial rise is
followed by a persistent fall, and retreatment with R5020 at 40 h
produces an abortive rise. Cyclin E levels fall to low levels as the
cells transit the cell cycle in the first 24 h after progesterone,
then rise spontaneously to very high levels and remain high, in cells
that receive no further treatment. This lack of cyclin E degradation
suggests that the cells are blocked in late G1 and cannot enter S phase
(44). Retreatment of the cells with R5020 at 40 h lowers cyclin E
levels only minimally, and the flow cytometry data confirm that these
cells do not resume cycling.

View larger version (29K):
[in this window]
[in a new window]
|
Figure 4. Progesterone Treatment Arrests T47D-YB Cells in G1
of the Second Cycle by Up-Regulating p21 and p27Kip1 and
Down-Regulating cdk2 Activity
A, Growth, cyclin, and cdk inhibitor levels. T47D-YB cells were
treated with progesterone at time 0 (black arrow), and
again at 40 h ( ) or left untreated ( ) as shown in Fig. 3 .
Cells were harvested every 46 h for 80 h, and the percent in
S+G2/M was measured by flow cytometry (dashed
lines; see Fig. 3 ). Parallel sets of cells were lysed in
Laemmli buffer, and extracts normalized to total protein were
resolved by SDS-gel electrophoresis and immunoblotted with antibodies
to the cyclins and cdk inhibitors shown: cyclins D1, D3, and E; Cdk p21
and p27Kip1. Protein bands were detected by enhanced
chemiluminescence and quantitated by densitometry, and their levels
were normalized to pSTAIRE levels determined in parallel. B, Rb
Immunoblot. T47D-YB cells were treated with progesterone at time 0, and
parallel sets were harvested every 6 h for 72 h. Cells were
lysed in Laemmli buffer, and extracts were normalized to total protein
level, resolved by SDS-PAGE, and immunoblotted with an antibody
directed against Rb. C, Cyclin-dependent protein kinase activity.
T47D-YB cells were treated with progesterone (Prog.) at time 0 or
untreated and harvested at the indicated times (Hrs.). cdk2 was
immunoprecipitated from T47D-YB cell lysates, and immune complex kinase
assays were performed using recombinant glutathione
S-transferase-pRb fusion protein as a substrate as
described (38).
|
|
Because progesterone produces a prolonged growth-refractory
state, protein levels of cdk inhibitors were also measured (Fig. 4A
).
We find that T47DCO cells and their descendents do not
express p16 (p16INK4,MTS1) (45), but they express p21
(p21Cip1,Waf1,Sdi1) (20) and p27Kip1
(p28lck1) (46). A rise in protein levels of the inhibitors
begins as cyclin levels are declining. The levels of p21 increase
first, peak approximately 36 h after the initial progesterone
pulse, and then fall. This decline can be delayed approximately 18
h by retreatment of the cells with progesterone at 40 h. Thus
elevated p21 levels are transiently stabilized by the second
progesterone pulse. The levels of p27Kip1 remain relatively
unchanged for 3640 h after the initial progesterone treatment and
then start to climb as the cells arrest. Its levels eventually fall
(not shown here, but see Fig. 7D
) in the absence of a second hormone
pulse, as the cells spontaneously recover their ability to proliferate.
This recovery rate varies somewhat among experiments and appears to be
related to the fall in p27. However, a second hormone dose produces
even higher and sustained levels of both p21 and p27Kip1
resulting in failure to recover and persistent growth suppression (see
Fig. 6B
).

View larger version (45K):
[in this window]
[in a new window]
|
Figure 7. Progesterone-Arrested Cells Can Mount a Transient
Proliferative Response to EGF
A, EGF effects on naive T47D-YB cells. T47D-YB cells growing under
control conditions without progesterone were treated with 10
nM recombinant human EGF at time 0. Cells were harvested
every 6 h, and the percent of cells in S+G2/M was
measured flow cytometrically and compared with EGF-untreated controls,
set at 0. B, Chronic EGF and progestins. Parallel sets of T47D-YB cells
were treated daily for 6 days with R5020 only ( ), R5020 + EGF ( ),
EGF only ( ), or left untreated (). Cells were harvested daily and
their number counted. C, Proliferative effects of EGF after a pulse of
progesterone. Parallel sets of T47D-YB cells were treated with
progesterone at time 0. Control cells were left untreated for the
subsequent 80 h (dashed lines). Parallel sets
received 10 nM EGF starting at 36, 46, 52, 58, and 64
h after time 0, and the percent of cells in S+G2/M was
monitored flow cytometrically over the subsequent 36 h for each
treatment group. D, p21 and p27Kip1 levels after a pulse of
progesterone. Cells from panel C, which received progesterone at time 0
and no further treatment, were harvested periodically as shown and
lysed in Laemmli buffer. The lysates were normalized to total protein
levels, resolved by SDS-PAGE, and immunoblotted with anti-p21 and
anti-p27Kip1 antibodies, and levels of the inhibitors were
determined densitometrically and normalized to pSTAIRE levels in the
same lysates. The data were plotted as a percent of the maximum level
for each inhibitor, set at 100%. E, Immunoblot of p21 and
p27Kip1 levels after a pulse of progesterone. T47D-YB cells
treated with progesterone at time 0 were harvested periodically as
shown and lysed in Laemmli buffer. The lysates were normalized to
pSTAIRE levels, resolved by SDS-PAGE, and immunoblotted as in panel
D.
|
|

View larger version (18K):
[in this window]
[in a new window]
|
Figure 6. A Brief Progesterone Pulse Leads to Prolonged
Progesterone Resistance Accompanied by Elevated Levels of cdk
Inhibitors
A, Time course for restoration of progestin responsiveness after a
brief progesterone pulse. Parallel sets of T47D-YB cells were treated
with progesterone at time 0 (not shown), and either 48 h later, or
every 6 h thereafter up to 78 h later, they were again
treated with progesterone. The ability of the second progesterone dose
to induce a proliferative response was monitored for the subsequent
36 h. Cells were harvested at the time points shown and percent in
S+G2/M were measured by flow cytometry and were compared
with control cells (%S+G2/M set at 0) that had received no
second hormone treatment (not shown). B, Effects of single
vs. daily progestin treatments on cell proliferation.
Parallel sets of T47D-YB cells were untreated ( ), treated once with
progesterone at time 0 (), or treated with progesterone ( ) or
R5020 ( ) daily. Cells were harvested as shown over a 6-day period,
and the average number of cells, in duplicate flasks, were counted. C,
Levels of p21 and p27Kip1 after chronic progesterone. Sets
of cells from the daily progesterone treatment (panel B,
above) were harvested and lysed in Laemmli buffer.
Lysate concentrations were normalized to total protein levels, resolved
on SDS-PAGE, immunoblotted with anti-p21 or anti-p27Kip1
antibodies, and relative cdk inhibitor levels were quantitated by
densitometry and normalized to pSTAIRE levels determined in parallel
blots. Bars represent the average of duplicate assays.
|
|
Since the signals from the G1 cyclins and the cdk inhibitors are
integrated into the Rb transcriptional regulatory pathway (40), the
protein levels of Rb and its phosphorylation state were measured at 6-h
intervals for 72 h following the two hormone pulses (Fig. 4B
). In
the first 612 h, levels of Rb are high but the protein is
predominantly in its inactive hyperphosphorylated state. In this
period, lacking sufficient amounts of inhibitory Rb, the cells undergo
one round of cell division. However, coincident with the G1 arrest in
the second cycle, 1824 h after progesterone treatment, significant
levels of the hypophosphorylated active repressor form of Rb are
present. Thereafter, total Rb protein levels down-regulate by more than
90%, consistent with G1 cell cycle arrest in many systems (47). This
decline occurs in the presence (not shown) or absence (Fig. 4B
) of a
second hormone pulse at 40 h.
Because progesterone regulates the levels of the cdk inhibitors,
p21 and p27, in a complex manner, we examined the activity of the
cyclin-dependent protein kinase, cdk2, by its ability to phosphorylate
purified recombinant pRb (Fig. 4C
). cdk2 is regulated both by p21 and
p27kip1 (20, 40, 41, 46). In untreated control cells at
early time points after cell plating, cdk2 activity is low and minimal
changes in cell proliferation are observed (Figs. 6B
and 7B
). cdk2
activity rises as untreated cells begin to cycle (32 h) and then falls
as cells reach confluence and become contact inhibited (72 h).
Interestingly, progesterone up-regulates cdk2 activity early (12 h),
then suppresses it at later time points (4872 h) relative to
untreated controls. Thus, progesterone exerts biphasic effects on cdk
activity, consistent with its biphasic effects on cell
proliferation.
Indeed, the profound quality of the arrest in G1 is further confirmed
by analysis of cyclin A and B levels as shown in Fig. 5
. These cyclins are produced in S- and
G2-phase, respectively, in preparation for mitosis (35, 37, 38). In
progesterone-treated T47D-YB cells, the levels of both cyclins reach a
peak during the initial proliferative burst, but then fall
precipitously to almost undetectable levels for at least 72 h
(Fig. 5
, A and B), and they cannot be rescued by a second hormone pulse
at 41 h (Fig. 5C
).
When do T47D-YB cells regain sensitivity to progestins? To assess this
(Fig. 6A
), parallel sets of cells were
treated with progesterone at time zero, then exposed to R5020 starting
48 h later, or every 6 h thereafter. For each set of time
points, the ability of R5020 to induce proliferation was monitored for
the subsequent 36 h. Each hormone-treated set was compared with
control cells that had not received the second R5020 dose to monitor
spontaneous recovery. Figure 6
shows that resistance to R5020 persists
until approximately 72 h after the initial progesterone dose, at
which point R5020 produces a brisk proliferative response (Fig. 6A
),
coincident with spontaneous recovery (not shown, but see Fig. 7C
).
Thus, only when they are poised to resume growing spontaneously, do the
cells regain sensitivity to progestins. The extent and duration of this
second proliferative burst resemble that of the initial response seen
in naive, hormone-untreated cells (Figs. 1
and 2
). The recovery time
varies somewhat among experiments, depending on the basal cell
proliferation rate at time zero; cells with a high basal rate, usually
late passage cells, recover more quickly. In general, T47D-YB breast
cancer cells remain in stasis for approximately 3 days after a brief
pulse of progesterone (recall the t1/2 is 24 h),
but then resume growing at the same rate as controls (Fig. 6B
). On the
other hand, repeated exposure to progesterone or R5020 every 48 h
produces permanent growth arrest (Fig. 6B
). This arrest is associated
with a 12- to 15-fold increase in the levels of p21 and a 6- to 7-fold
increase in the levels of p27Kip1 (Fig. 6C
).
EGF Induces a Proliferative Response in Progesterone-Resistant
Cells
To determine whether, during the
progesterone-resistant state, T47D-YB cells are also resistant to other
mitogenic signals, we tested the effects of EGF. This mitogen is an
important growth factor in breast cancers, and clinically, an inverse
relationship exists between steroid receptor loss (with concomitant
hormone resistance) and the expression of EGF receptors (48, 49, 50). We
therefore tested the relationship, if any, between progesterone
resistance and EGF growth sensitivity (Fig. 7
, A-E). Control T47D-YB cells express
low levels of EGF receptors, which are functionally competent in their
ability to signal to downstream cytoplasmic effectors, since a 10
nM pulse of EGF strongly induces mitogen-activated protein
(MAP) kinase activity (not shown). However, the naive cells are
resistant to the growth-stimulatory effects of EGF (Fig. 7A
). In this
study, cells that had received no prior treatment were incubated with
10 nM recombinant human EGF or left untreated, and the
percent of cells in S+G2/M was measured every 6 h for
30 h. As shown, the proliferation of cells treated acutely with
EGF did not differ significantly from controls.
To determine whether chronic EGF treatment affects growth, cells
received EGF continuously for 6 days in the presence or absence of
continuous R5020, and their proliferation rate was compared with that
of untreated or R5020-treated cells (Fig. 7B
). As shown, EGF alone does
not accelerate growth above the control rate, and it cannot relieve the
growth suppression produced by continuous R5020.
Surprisingly therefore, T47D-YB cells can be sensitized to the
proliferative effects of EGF by a brief progesterone pulse (Fig. 7C
).
In this study, sets of T47D-YB cells that had been pretreated with
progesterone at time 0 were challenged with EGF at various time points,
starting at 36 h. Control sets received no second progestin
treatment to monitor spontaneous recovery from the progesterone-induced
arrest. While EGF given 36 h after progesterone was ineffective,
the cells acquire sensitivity to EGF starting approximately 46 h
after progesterone pretreatment and exhibit an extensive proliferative
burst after a 6-h lag. Cells treated with EGF 52 h after
progesterone respond even faster. Recall that at these time points the
cells are insensitive to progesterone (Fig. 6
) and have not recovered
spontaneously (Fig. 7C
, dashed line). These and other
studies (not shown) suggest that there is a critical period during
progesterone-induced growth arrest, in which T47D-YB cells acquire
sensitivity to the proliferative effects of EGF, which accelerates
their reentry into the cell cycle.
What accounts for this brief sensitivity to EGF? Figure 7D
shows that
after the progesterone pulse, p21 levels rise, peak at approximately
30 h, and then fall by 36 h, at a time preceding the rise in
p27Kip1 levels. Figure 7E
shows a similar pattern from
another experiment, in which it is evident that approximately 48 h
after a single progesterone pulse, there is a brief period of time
characterized by relatively low levels of both inhibitors, during which
EGF can influence cell proliferation. This pattern occurs only after
the initial signal produced by the short half-life of one progesterone
pulse. More prolonged progestin exposure, produced either by repeated
treatment with progesterone or by continuous treatment with a poorly
metabolizable synthetic progestin such as R5020, prevents or slows the
fall in p21 levels (Fig. 4
) so that this event overlaps with, rather
than precedes, the rise in p27Kip1. We conclude that EGF
cannot overcome the continuous inhibitor levels produced by a sustained
progestin signal, as shown in Fig. 7B
.
However, the brief window, characterized by low inhibitor levels after
one pulse of progesterone, differs from the hormone-untreated condition
in one respect. Namely, that EGF receptors are strongly up-regulated by
the progesterone pulse (Fig. 8
). These
data, derived from immunoblots, show that progesterone treatment
increases the number of EGF receptors by 3- to 5-fold between 24 and
48 h. Similar effects of progestins have been previously described
(51, 52).

View larger version (38K):
[in this window]
[in a new window]
|
Figure 8. One Dose of Progesterone Up-Regulates the Number of
EGF Receptors per Cell
T47D-YB cells were treated with 30 nM progesterone at time
0 or left untreated. Sets of cells were harvested at the times shown
and counted, and EGF receptor levels were measured by immunoblotting of
cell membrane preparations normalized to cell number. The data
represent the average of three experiments. Error bars depict the range
among measures.
|
|
 |
DISCUSSION
|
---|
We demonstrate here, under conditions in which the proliferative
actions of progesterone can be isolated from those of other mitogens,
and in which PR levels are autonomously controlled, that this steroid
hormone elicits a single round of mitosis in breast cancer cells, after
which the cells chronically arrest in late G1 of the second cycle in a
persistent progesterone-resistant state. Clearly, the cellular
conditions that unmasked this property of progesterone are artificial
(34). Nevertheless, they begin to allow study of a hormone whose
proliferative effects have been intensely disputed in part because of
their complexity (1). We believe that by simplifying the model we can
dissect out the unique role that progesterone plays in physiological
systems in which its actions are otherwise intricately regulated by
cross-talk with other steroid hormones and growth factors.
Continuous Progesterone Is Autoinhibitory
The immediate response of proliferating breast cancer cells to
progesterone is an acceleration of the cell cycle driven by increased
levels of cyclins D1 (8), D3, and E and by accumulation of inactive
forms of Rb in the face of persistent low steady state levels of p21
and p27Kip1. Under these conditions cyclin D-cdk4 complexes
accumulate above the inhibitory threshold of p27Kip1 (53),
allowing the cells to progress past the G1 restriction point and enter
mitosis. Because the breast tumor cells used in these studies are
proliferating rapidly initially (at a "low" proliferation rate,
1525% of cells are in S+G2/M at any time), and
progesterone more than doubles this rate (leading to more than 50% in
S+G2/M), the cells proceed through mitosis and reenter G1
of the second cycle in a partially synchronized state. At this point
however, the cells are unable to adequately replenish the depleted
stores of cyclin Ds, Rb protein levels are extensively down-regulated,
cyclin E levels rise sharply, followed first by rising p21, and later
by rising p27Kip1 levels, while cdk2 activity declines.
Cyclin A, required for progression through S phase and cyclin B, the
primary mitotic cyclin, are completely down-regulated. Taken together
these data indicate that the cells are arrested late in G1 (44).
One surprising finding is that additional progesterone cannot override
the growth suppression produced by the first progesterone dose, despite
the presence of adequate levels of transcriptionally competent PR.
Thus, the proliferative block is not at the level of the PR-signaling
system. In fact, we propose that the growth arrest may actually require
the presence of functional PR, since it appears to be due to sustained
up-regulation of p21 and p27Kip1 produced by a positive
feedback loop initiated by at least two progestin treatments, given
before the time at which the cells would spontaneously recover. Thus,
we believe that sustained progesterone is autoinhibitory, in contrast
to transient progesterone, which is stimulatory. This model has
important implications for the scheduling of progestin treatments in
clinical settings, since it predicts that the effects of continuously
administered progestins (54) differ significantly from those of
episodically or cyclically administered progestins (13, 14); the former
would be growth inhibitory and the latter stimulatory. These data also
suggest that the cyclical progesterone of the menstrual cycle can have
different physiological consequences than the continuous progesterone
of pregnancy. A model in which the rate and duration of progesterone
treatment control the type of response observed would reconcile
contradictory views that this hormone is either proliferative or
differentiative. A similar model, in which a proliferative
vs. differentiative end point is controlled by the duration
of MAP kinase signaling was recently described (55).
The mechanism of progesterone-mediated induction of p21 and p27 is
unknown. However, aside from its p53-dependent regulation in response
to DNA damage, p53-independent transcriptional activation of p21 has
recently been shown to be regulated by the MAP kinase pathway after
stimulation of cells with growth factors (56). We are currently
investigating the mechanism of p21 and p27 regulation by progesterone.
Interestingly, in addition to its action as a cyclin-dependent protein
kinase inhibitor and cell-cycle inhibitor, p21, at low concentrations,
promotes the assembly of active cyclin/cdk/proliferating cell nuclear
antigen complexes and exerts a positive influence on cell growth;
kinase activity increases 3-fold upon the addition of low
concentrations of p21 to lysates containing cyclin A and cdk2 (57).
Thus, quaternary complexes containing one p21 molecule are fully
active, while inhibition of cyclin kinases requires association of more
than one p21 subunit. This may explain the biphasic effects of
progesterone on breast cancer cell growth. In this model, the initial
proliferative burst is supported by the assembly and activation of
cdk/cyclin/proliferating cell nuclear antigen/p21 complexes. However,
as p21 and p27 expression increases, these quaternary complexes become
inactive due to the addition of multiple inhibitor subunits, and the
cells are growth inhibited. A second exposure to progesterone produces
sustained elevation of p21 and prolongs growth inhibition. Consistent
with this hypothesis, Matsushine et al. (58) showed that
cyclin D and cdk4 do not associate in serum-starved cells, but undergo
association and activation upon serum stimulation, a condition that
increases p21 levels in a p53-independent manner. Similarly, LaBaer
et al. (59) found that the addition of low concentrations of
p21 and p27 lead to a 35- and 80-fold increase in the assembly and
activity of cyclin D-cdk4 complexes, respectively, while high
concentrations inhibited activity, suggesting new roles for these
inhibitors as adaptor proteins that assemble and program kinase
complexes (59).
Progesterone Enhances Sensitivity to EGF and Up-Regulates EGF
Receptors
Failure of progestins to reinitiate proliferation after a single
progesterone pulse is not due to insensitivity of the cell-cycling
machinery, since an alternate mitogenic signal emanating from the cell
surface can transiently reactivate proliferation. The mechanisms by
which one pulse of progesterone sensitizes the cells to the
proliferative effects of EGF appears to be related to its ability to
up-regulate the levels of EGF receptors, as previously described (51, 52). Untreated T47D-YB cells do not respond to proliferative signals by
EGF (Fig. 7A
), although the cells express low levels of immunoreactive
EGF receptors (Fig. 8
), and they respond to EGF by activating the
downstream effectors, p42 and p44 MAP kinases (not shown). Thus, the
EGF receptor-mediated signal transduction pathway leading to activation
of cytoplasmic kinase cascades known to regulate cellular processes
including growth (60), is functionally intact in these cells. At high
EGF receptor levels, however, EGF appears to be able to induce the
arrested cells to reenter the cell cycle, as long as the levels of the
cdk inhibitors are relatively low. It is possible that at high levels,
EGF receptors can engage novel signaling proteins (61) or be capable of
associating with novel cell-surface partners (62) that are unavailable
at low receptor concentrations. Similar, phenotypically different
response, dependent on the number of active cell surface receptors,
have been described (63, 64, 65).
On the other hand, our data suggest that the high levels of EGF
receptors cannot overcome the inhibitory effects of high levels of p21
or p27Kip1 produced by a second dose of progesterone. This
may explain EGF-dependent proliferation after a single pulse of
progesterone but resistance after a second pulse or during sustained
progesterone treatment. We have shown that one progesterone pulse leads
to a transient rise in p21 levels and that p27Kip1 levels
start to rise as p21 levels are falling. Therefore we postulate that
after a single progesterone pulse, there is a transient window of EGF
responsiveness generated by increased EGF receptor levels and falling
p21 levels, before the rise in p27Kip1 levels. A second
dose of progesterone delays the fall in p21 and increases the levels of
p27Kip1 (Fig. 4
), eliminating the window to EGF
responsiveness. This suggests that in breast cancer cells,
proliferative sensitivity to EGF is dependent on the cell cycle state
and progestational history of the cells.
There is considerable evidence linking the EGF and progesterone
signaling pathways in breast cancer. This includes attenuation of
progestin responsiveness and decreases in PR levels in cells treated
with EGF (66); augmentation of the proliferative, differentiative, and
transcriptional effects of progestins by cotreatment with EGF (67, 68, 69);
and progestin-specific regulation of EGF and EGF receptor levels (Fig. 8
and Refs. 49, 51, and 66). There are also provocative clinical data
linking enhanced expression of EGF receptors to acquisition of steroid
hormone resistance in breast cancer (48, 50).
Is Progesterone Proliferative or Differentiative?
Proliferation and differentiation are complex processes governed
by the concerted activity of multiple regulatory factors. Both
processes appear to have the common requirement that cells stop in G1
to await appropriate directional signals (16, 18, 19). Our
demonstration that progesterone can advance cells to this checkpoint,
while it sensitizes the cells to the actions of a growth factor,
provides a model that may reconcile opposing views that progesterone is
either a proliferative or a differentiative hormone. We suggest that
progesterone is neither, but that it is a competency factor necessary
to drive cells into either pathway, and that breast cell proliferation
and differentiation are intricately connected. In this model,
progesterone accelerates cells to the G1 checkpoint in the second
cycle, whereupon other, possibly tissue-specific, factors determine the
fate of the cell. Therefore the final state of progesterone target
tissues is determined by cross-talk between progesterone and growth or
differentiative factors that remain to be defined. However, the
progesterone treatment regimen may be a key factor in the ultimate
response produced, with transitory progesterone being permissive of
such cross-talk while sustained progesterone is inhibitory.
 |
MATERIALS AND METHODS
|
---|
Cell Lines and Reagents
Wild type PR-positive T47DCO breast cancer cell
lines, their monoclonal PR-negative T47D-Y derivatives, and T47D-Y
cells stably expressing either A- or B receptors (T47D-YA or T47D-YB
cells) were previously described (34). Cells are routinely cultured in
75-cm2 plastic flasks or six-well multiwell plates and
incubated in 5% CO2 at 37 C in a humidified environment.
The stock medium consists of Eagles Minimum Essential Medium with
Earles salts (MEM), containing L-glutamine (2
mM) buffered with sodium bicarbonate (4 µg/liter) and
HEPES (4.8 µg/liter), insulin (6 ng/ml), and 5% FCS (Hyclone, Logan,
UT) without antibiotics. For routine subculturing, cells are diluted
1:20 into new flasks once per week, and medium is replaced every 23
days. Cells are harvested by incubation in Hanks EDTA for 15 min at
37 C.
Antibodies were obtained from the following sources: anti-cyclin A,
-cyclin B1, and -cyclin D1 were from Upstate Biotechnology (Lake
Placid, NY); anti-cyclin D3 and E were from Pharmingen (San Diego, CA);
anti-p21 and anti-p27Kip1 were from Santa Cruz
Biotechnology (Santa Cruz, CA); anti-pRb was a gift from Wen-Hwa Lee
(University of Texas Health Science Center, San Antonio, TX); anti-EGF
receptor 20.3.6 was a gift from Roger Davis (University of
Massachusetts Medical School, Worcester, MA); anti-PR AB52 and B30 were
produced in our laboratories (49); and horseradish
peroxidase-conjugated secondary antibodies were from Bio-Rad
Laboratories (Hercules, CA).
Flow Cytometry
Cells (2 x 105) were plated into duplicate
wells of six-well plastic dishes with 3 ml of serum-containing medium.
After 24 h, progesterone, or the synthetic agonist R5020
(Roussel-Uclaf, Romainville, France) or the antiprogestins RU486
(Roussel-Uclaf) or ZK98299 (Schering AG, Berlin, Germany) were added in
ethanol, at final concentrations of 30 nM, 100
nM, or 1 µM, respectively. Control medium
contained only ethanol. Some cells received 60 ng/ml (10
nM) human recombinant EGF (Upstate Biotechnology,
Inc.).
Cells were harvested at the start of treatment (control, zero time) and
every 4 or 6 h after hormone addition, into 1 ml of Hanks EDTA
and vigorously pipetted. The cell suspension was pelleted, resuspended
into 1 ml of Krishans stain (70) containing propidium iodide and
ribonuclease (RNase), and again vigorously pipetted. Samples were
cooled to 4 C, and 10,000 cells were analyzed on an Epics 752 flow
cytometer (Coulter Electronics, Hialeah, FL), using an incident beam
from an argon laser at 488 nm, 500 mW. The cells were gated on forward
angle vs. 90° light scatter to eliminate cellular debris
and doublets. Red fluorescence, corresponding to DNA, was collected
through a 590-nm longpass filter, and histograms of DNA content
vs. cell number were constructed. Cell cycle analyses of the
DNA histograms were performed using the ModFit Analysis program
(Veritey Software House, Topsham, ME), which provides fits for the
GO/G1, S and G2/M fractions of the
population. The S- and G2/M-phase fractions were combined
into a single growth fraction. In some figures, the percent of cells in
S+G2/M in the hormone-treated sets were compared with the
percent of cells in S+G2/M in the untreated controls, whose
levels were set at 0. For long-term growth studies, cells were
harvested into 1 ml of Hanks EDTA and pipetted vigorously to obtain
single-cell suspensions, and aliquots were counted using a
hemocytometer.
Immunoblotting
For measurements of PR, whole cell extracts were prepared in 0.4
M KCl as previously described (27, 34). Receptors were
resolved by electrophoresis on an 11% polyacrylamide gel containing
SDS and then transferred to nitrocellulose. After incubation with
anti-PR monoclonal antibodies AB-52 and B-30 (71), the receptor bands
were detected by enhanced chemiluminescence (Amersham, Arlington
Heights, IL). For cell cycle proteins, cells were harvested at 5080%
confluence and washed in PBS. Aliquots were removed for analysis by
flow cytometry to simultaneously determine cell cycle distribution. The
remaining cells were resuspended in Laemmli sample buffer (72) at
14 x 107 cells per ml, immediately boiled for 5
min, sheared through a syringe needle to reduce viscosity, aliquoted,
and stored at -80 C. Volumes of cell extracts normalized to
approximately 50 µg total protein, as measured by Ponceau S, were
subjected to gel electrophoresis. For measurement of EGF receptors,
cells were resuspended in RIPA buffer (0.1 M NaCl, 6
mM Na2HPO4, 4 mM
NaH2PO4, 1% deoxycholic acid, 1% NP-40, and
0.1% SDS) (61) for 10 min at 4 C, and centrifuged at 10,000 rpm to
produce a membrane-containing pellet. The pellet was reextracted with
RIPA and repelleted, and membranes (60 µg) were resuspended in four
volumes of water, sheared through a 28-gauge needle, boiled in Laemmli
sample buffer, and resolved by electrophoresis on an 8% polyacrylamide
gel. Proteins were transferred for 45 min at 0.5 A to Immobilon P
membranes (Millipore, Bedford, MA) using a Genie Electroblotter (Idea
Scientific, Minneapolis, MN). After incubation with the appropriate
antibodies, protein bands were detected by enhanced chemiluminescence
(Amersham). Film exposures ranged from 2 sec to 1 h depending on
the primary antibody. Bands were quantitated using a digital scanner
and the Image program (NIH) and, where appropriate, normalized to
levels of pSTAIRE sequence-containing cdks.
Transfection and Transcription
T47D-YB cells were plated and grown in 100-mm2 cell
culture plates in MEM supplemented with 5% FCS. Progesterone (30
nM) was added 40 h prior to completion of
transfection. Transfection of plasmid DNA into cells was performed
24 h after the start of progesterone treatment by calcium
phosphate coprecipitation using 1 µg of the
PRE2-TATAtk--CAT reporter (27), 3 µg of the
ß-galactosidase expression plasmid PCH110 (Pharmacia, Piscataway, NJ)
to correct for transfection efficiency, and 15 or 16 µg Bluescribe
carrier plasmid (Stratagene, La Jolla, CA) for a total of 20 µg DNA,
as previously described (27). Sixteen hours later transfection was
completed when the medium was aspirated, and the cells were shocked at
room temperature for 4 min with 5 ml HBSS containing 20% glycerol.
After the cells were washed twice with 10 ml serum-free MEM to remove
the glycerol, 10 ml MEM containing 5% FCS were added per dish, either
without or with 30 nM progesterone or R5020. Cells were
harvested after an additional 24 or 48 h. Cells in duplicate
plates were lysed by freeze-thawing in 200 µl of 0.25 M
Tris, pH 7.8. Lysates (50 µl) were assayed for ß-galactosidase
activity, and normalized aliquots were assayed for CAT activity by TLC
as described (27).
 |
ACKNOWLEDGMENTS
|
---|
We thank L. Miller, R. Powell, L. Tung, and G. Takimoto for help
with portions of these studies, C. Sartorius who constructed the YA and
YB cells, Wen-Hwa Lee and Roger J. Davis for antibodies, and Neal Rosen
for helpful discussions.
 |
FOOTNOTES
|
---|
Address requests for reprints to: Kathryn Horwitz, Department of Medicine, Division of Endocrinology, Box B151, University of Colorado Health Science Center, 4200 East Ninth Avenue, Denver, Colorado 80262.
This work was supported in part by NIH Grants CA-26869 and DK-48238, by
Grant DAMD1794-54026 from the U.S. Army Medical Research and
Development Command, and by the National Foundation for Cancer Research
(to K.B.H.); CA-58187 (to R.A.S.); U.S. Army AIBF1563 (to T.A.L.);
Colorado Cancer League (to C.A.L.); and by the Flow Cytometry and
Tissue Culture Core Laboratories of the University of Colorado Cancer
Center. S.D.G. was supported by a graduate student stipend from the
Lucille P. Markey Charitable Trust.
Received for publication February 17, 1997.
Revision received June 24, 1997.
Accepted for publication July 15, 1997.
 |
REFERENCES
|
---|
-
Clarke CL, Sutherland RL 1990 Progestin regulation of
cellular proliferation. Endocr Rev 11:266302[Medline]
-
Horwitz KB 1992 The molecular biology of RU486. Is there a
role for antiprogestins in the treatment of breast cancer? Endocr Rev 13:146163[Medline]
-
Horwitz KB, McGuire WL, Pearson OH, Segaloff A 1975 Predicting response to endocrine therapy in human breast cancer: a
hypothesis. Science 189:726727[Medline]
-
Clark GM, McGuire WL, Hubay CA 1983 Progesterone receptors as
a prognostic factor in stage II breast cancer. N Engl J Med 309:13431347[Abstract]
-
Lydon JP, DeMayo FJ, Funk CR, Mani SK, Hughes AR, Montgomery
Jr CA, Shyamala G, Conneely OM, OMalley BW 1995 Mice lacking
progesterone receptor exhibit pleiotropic reproductive abnormalities.
Genes Dev 9:22662278[Abstract]
-
Sicinski P, Donaher JL, Parker SB, Li T, Fazeli A, Gardner H,
Haslam SZ, Bronson RT, Elledge SJ, Weinberg RA 1995 Cyclin D1 provides
a link between development and oncogenesis in the retina and breast.
Cell 82:621630[Medline]
-
Musgrove EA, Hamilton JA, Lee CSL, Sweeney KJE, Watts CKW,
Sutherland RL 1993 Growth factor, steroid, and steroid antagonist
regulation of cyclin gene expression associated with changes in
T-47D human breast cancer cell cycle progression. Mol Cell Biol 13:35773587[Abstract]
-
Musgrove EA, Lee CS, Buckley MF, Sutherland RL 1994 Cyclin D1
induction in breast cancer cells shortens G1 and is sufficient for
cells arrested in G1 to complete the cell cycle. Proc Natl Acad Sci USA 91:80228026[Abstract]
-
Wang TC, Cardiff RD, Zukerberg L, Lees E, Arnold A, Schmidt
EV 1994 Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic
mice. Nature 369:669671[CrossRef][Medline]
-
Colditz GA, Hankinson SE, Hunter DJ, Willett WC, Manson JE,
Stampfer MJ, Hennekens C, Rosner B, Speizer FE 1995 The use of
estrogens and progestins and the risk of breast cancer in
postmenopausal women. N Engl J Med 332:15891593[Abstract/Free Full Text]
-
Cummings SR 1991 Evaluating the benefits and risks of
postmenopausal hormone therapy. Am J Med 91:14S18S
-
Stanford JL, Weiss NS, Voigt LF, Daling JR, Habel LA, Rossing
MA 1995 Combined estrogen and progestin hormone replacement therapy in
relation to risk of breast cancer in middle-aged women. JAMA 274:137142[Abstract]
-
Anderson TJ, Battersby S, King RJB, McPherson K, Going JJ 1989 Oral contraceptive use influences resting breast proliferation. Hum
Pathol 20:11391144[Medline]
-
Going JJ, Anderson TJ, Battersby S, Macintyre CCA 1988 Proliferative and secretory activity in human breast during natural and
artificial menstrual cycles. Am J Pathol 130:193204[Abstract]
-
Potten CS, Watson RJ, Williams GT 1988 The effect of age and
menstrual cycle upon proliferative activity of normal human breast.
Br J Cancer 58:163170[Medline]
-
Halevy O, Novitch BG, Spicer DB, Skapek SX, Rhee J, Hannon GH,
Beach D, Lassar AB 1995 Correlation of terminal cell cycle arrest of
skeletal muscle with induction of p21 by MyoD. Science 267:10181021[Medline]
-
Pardee AB 1989 G1 events and regulation of cell proliferation.
Science 246:603608[Medline]
-
Parker SB, Eichele G, Zhang P, Rawls A, Sands AT, Bradley A,
Olson EN, Harper JW, Elledge SJ 1994 p53-independent expression of
p21Cip1 in muscle and other terminally differentiating
cells. Science 267:10241027
-
Steinman RA, Hoffman B, Iro A, Guillouf C, Liebermann DA,
El-Houseini ME 1994 Induction of p21 (WAF-1/CIP1) during
differentiation. Oncogene 9:33893396[Medline]
-
Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D 1993 p21 is a universal inhibitor of cyclin kinases. Nature 366:701704[CrossRef][Medline]
-
Skapek SX, Rhee J, Spicer DB, Lassar AB 1995 Inhibition of
myogenic differentiation in proliferating myoblasts by cyclin
D1-dependent kinase. Science 267:10221024[Medline]
-
Horwitz KB, McGuire WL 1978 Estrogen control of progesterone
receptor in human breast cancer: correlation with nuclear processing of
estrogen receptor. J Biol Chem 253:22232228[Medline]
-
Dickson RB, Lippman ME 1995 Growth factors in breast cancer.
Endocr Rev 16:559589[Medline]
-
Musgrove EA, Lee CSL, Sutherland RL 1991 Progestins both
stimulate and inhibit breast cancer cell cycle progression while
increasing expression of transforming growth factor a, epidermal growth
factor receptor, c-fos, and c-myc genes. Mol Cell
Biol 11:50325043[Medline]
-
Horwitz KB, Alexander PS 1983 In situ photolinked
nuclear progesterone receptors of human breast cancer cells: subunit
molecular weights after transformation and translocation. Endocrinology 113:21952201[Abstract]
-
Meyer M-E, Quirin-Stricker C, Lerouge T, Bocquel M-T,
Gronemeyer H 1992 A limiting factor mediates the differential
activation of promoters by the human progesterone receptor isoforms.
J Biol Chem 267:1088210887[Abstract/Free Full Text]
-
Sartorius CA, Melville MY, Hovland AR, Tung L, Takimoto GS,
Horwitz KB 1994 A third transactivation function (AF3) of human
progesterone receptors located in the unique N-terminal segment of the
B-isoform. Mol Endocrinol 8:13471360[Abstract]
-
Tora L, Gronemeyer H, Turcotte B, Gaub M-T, Chambon P 1988 The
N-terminal region of the chicken progesterone receptor specifies target
gene activation. Nature 333:185187[CrossRef][Medline]
-
Boyd-Leinen PA, Fournier D, Thomas CS 1982 Nonfunctioning
progesterone receptors in the developed oviducts from
estrogen-withdrawn immature chicks and in aged nonlaying hens.
Endocrinology 111:3036[Abstract]
-
Graham JD, Yeates C, Balleine RL, Harvey SS, Milliken JS,
Bilous AM, Clarke CL 1995 Characterisation of progesterone receptor A
and B expression in human breast cancer. Cancer Res 55:50635068[Abstract]
-
Kato J, Hirata S, Nozawa A, Mouri N 1993 The ontogeny of gene
expression of progestin receptors in the female rat brain. J Steroid
Biochem Mol Biol 47:173182[CrossRef][Medline]
-
Spelsberg TC, Halberg F 1980 Circannual rhythms in steroid
receptor concentration and nuclear binding in the chick oviduct.
Endocrinology 107:12341244[Abstract]
-
Horwitz KB, Mockus MB, Lessey BA 1982 Variant T47D human
breast cancer cells with high progesterone-receptor levels despite
estrogen and antiestrogen resistance. Cell 28:633642[Medline]
-
Sartorius CA, Groshong SD, Miller LA, Powell RP, Tung L,
Takimoto GS, Horwitz KB 1994 New T47D breast cancer cell lines for the
independent study of progesterone B- and A-receptors: only
antiprogestin-occupied B-receptors are switched to transcriptional
agonists by cAMP. Cancer Res 54:38683877[Abstract]
-
Heichman KA, Roberts JM 1994 Rules to replicate by. Cell 79:557562[Medline]
-
Hunter T, Pines J 1994 Cyclins and cancer. II. Cyclin D and
CDK inhibitors come of age. Cell 79:573582[Medline]
-
King RW, Jackson PK, Kirschner MW 1994 Mitosis in transition.
Cell 79:563571[Medline]
-
Nurse P 1994 Ordering S phase and M phase in the cell cycle.
Cell 79:547550[Medline]
-
Sherr CJ 1994 G1 phase progression: cycling on cue. Cell 79:551555[Medline]
-
Weinberg RA 1995 The retinoblastoma protein and cell cycle
control. Cell 81:323330[Medline]
-
Peter M, Herskowitz I 1994 Joining the complex:
cyclin-dependent kinase inhibitory proteins and the cell cycle. Cell 79:181184[Medline]
-
Horwitz KB, Pike AW, Gonzalez-Aller C, Fennessey PV 1986 Progesterone metabolism in T47Dco human breast cancer cells. II.
Intracellular metabolic pathway of progesterone and synthetic
progestins. J Steroid Biochem 25:911916[CrossRef][Medline]
-
Beato M, Herrlich P, Schutz G 1995 Steroid hormone receptors:
many actors in search of a plot. Cell 83:851857[Medline]
-
Sherr CJ, Roberts JM 1995 Inhibitors of mammalian
G1 cyclin-dependent kinases. Genes Dev 9:11491163[CrossRef][Medline]
-
Serrano M, Hannon GJ, Beach D 1993 A new regulatory motif in
cell cycle control causing specific inhibition of cyclin D/cdk4. Nature 366:704707[CrossRef][Medline]
-
Polyak K, Kato JY, Solomon MJ, Sherr CJ, Massagué J,
Roberts JM, Koff A 1994 p27Kip1, a cyclin-cdk inhibitor,
links transforming growth factor-beta and contact inhibition to cell
cycle arrest. Genes Dev 8:922[Abstract]
-
Xu J-H, Hu S-X, Benedict WF 1991 Lack of nuclear RB
protein staining in G0/middle G1 cells: correlation to changes in total
RB protein level. Oncogene 6:11391146[Medline]
-
Chrysogelos SA, Dickson RB 1994 EGF receptor expression,
regulation, and function in breast cancer. Breast Cancer Res Treat 29:2940[Medline]
-
Dotzlaw H, Miller T, Karvelas J, Murphy LC 1990 Epidermal
growth factor gene expression in human breast cancer biopsy
samples: relationship to estrogen and progesterone receptor gene
expression. Cancer Res 50:42044208[Abstract]
-
Fox SB, Smith K, Hollyer J, Greenall M, Hastrich D,
Harris AL 1994 The epidermal growth factor receptor as a prognostic
marker: results of 370 patients and review of 3009 patients. Breast
Cancer Res Treat 29:4149[Medline]
-
Murphy LC, Dotzlaw H, Johnson Wong MS, Miller T, Murphy LJ 1991 Mechanisms involved in the evolution of progestin resistance in
human breast cancer cells. Cancer Res 51:20512057[Abstract]
-
Murphy LC, Murphy LJ, Shiu RPC 1988 Progestin regulation of
EGF receptor mRNA accumulation in T47D human breast cancer cells.
Biochem Biophys Res Commun 150:192196[Medline]
-
Kato J-Y, Matsuoka M, Polyak K, Massagué J, Sherr CJ 1994 Cyclic AMP-induced G1 phase arrest mediated by an inhibitor
(p27Kip1) of cyclin-dependent kinase 4 activation. Cell 79:487496[Medline]
-
Sedlacek SM, Horwitz KB 1984 The role of progestins and
progesterone receptors in the treatment of breast cancer. Steroids 44:467484[Medline]
-
Marshall CJ 1995 Specificity of receptor tyrosine kinase
signaling: transient vs. sustained extracellular
signal-regulated kinase activation. Cell 80:179185[Medline]
-
Liu Y, Martindale JL, Gorospe M, Holbrook NJ 1996 Regulation
of p21waf/cip1 expression through mitogen-activated protein kinase
signaling pathway. Cancer Res 56:3135[Abstract]
-
Zhang H, Hannon GH, Beach D 1994 p21-containing cyclin kinases
exist in both active and inactive states. Genes Dev 8:17501758[Abstract]
-
Matsushine H, Quelle DE, Shurtleff SA, Shibuya M, Sheer CJ,
Kato J-Y 1994 D-Type cyclin-dependent protein kinase activity in
mammalian cells. Mol Cell Biol 14:20662067[Abstract]
-
LaBaer J, Garrett MD, Stevenson LF, Slingerland JM, Sandhu C,
Chou HS, Fattaey A, Harlow E 1997 New functional activities for the p21
family of CDK inhibitors. Genes Dev 11:847862[Abstract]
-
Blenis J 1993 Signal transduction via the MAP kinases: proceed
at your own RSK. Proc Natl Acad Sci USA 90:58895882[Abstract]
-
Galcheva-Gargova Z, Konstantinov KN, Wu IH, Klier FG, Barrett
T, Davis RJ 1996 Binding of zinc finger protein ZPR1 to the epidermal
growth factor receptor. Science 272:17971802[Abstract]
-
Qian X, Decker SJ, Greene MI 1992 p185c-neu and
epidermal growth factor receptor associate into a structure composed of
activated kinases. Proc Natl Acad Sci USA 89:13301334[Abstract]
-
Dikic I, Schlessinger J, Lax I 1994 PC12 cells overexpressing
the insulin receptor undergo insulin-dependent neuronal
differentiation. Curr Biol 4:702708[Medline]
-
Traverse S, Seedorf K, Paterson H, Marshall CJ, Cohen P,
Ullrich A 1994 EGF triggers neuronal differentiation of PC12 cells that
overexpress the EGF receptor. Curr Biol 4:694701[Medline]
-
Yamauchi K, Pessin JE 1994 Enhancement or inhibition of
insulin signaling by insulin receptor substrate 1 is cell context
dependent. Mol Cell Biol 14:44274434[Abstract]
-
Sarup JC, Rao KVS, Fox CF 1988 Decreased progesterone binding
and attenuated progesterone action in cultured human breast carcinoma
cells treated with epidermal growth factor. Cancer Res 48:50715078[Abstract]
-
Haslam SZ, Counterman LJ, Nummy KA 1993 Effects of epidermal
growth factor, estrogen, and progestin on DNA synthesis in mammary
cells in vivo are determined by the developmental state of
the gland. J Cell Physiol 155:7278[Medline]
-
Krusekopf S, Chauchereau A, Milgrom E, Henderson D, Cato ACB 1991 Co-operation of progestational steroids with epidermal growth
factor in activation of gene expression in mammary tumor cells. J
Steroid Biochem Mol Biol 40:239245[CrossRef][Medline]
-
Modiano JF, Kokai Y, Weiner DB, Pykett MJ, Nowell PC, Lyttle
CR 1991 Progesterone augments proliferation induced by epidermal growth
factor in a feline mammary adenocarcinoma cell line. J Cell Biochem 45:196206[Medline]
-
Krishan A 1975 Rapid flow cytometric analysis of mammalian
cell cycle by propidium iodide staining. J Cell Biol 66:188193[Abstract]
-
Estes PA, Suba EJ, Lawler-Heavner J, Wei LL, Toft DO,
Horwitz KB, Edwards DP 1987 Immunologic analysis of human breast cancer
progesterone receptors. I. Immunoaffinity purification of transformed
receptors and monoclonal antibody production. Biochemistry 26:62506262[Medline]
-
Laemmli UK 1970 Cleavage of structural proteins during the
assembly of the head of bacteriophage T4. Nature 227:680685[Medline]